http://chineseinput.net/에서 pinyin(병음)방식으로 중국어를 변환할 수 있습니다.
변환된 중국어를 복사하여 사용하시면 됩니다.
신이식환자에서 B 형 및 C 형 간염의 유병율과 임상경과
양철우(Chul Woo Yang),신영신(Young Shin Sin),윤선애(Sun Ae Yoon),진동찬(Dong Chang Jin),안석주(Suk Joo Ahn),김용수(Yong Soo Kim),최의진(Euy Jin Choi),장윤식(Yoon Sik Chang),윤영석(Young Suk Yoon),방병기(Byung Kee Bang) 대한내과학회 1994 대한내과학회지 Vol.47 No.5
Objectives: To evaluate the prevalence and clinical course of HBsAg positive and anti-HCV positive renal transplant recipients. Methods: According to serologic result, we divided the patients into HBsAg positive (HBV) and anti-HCV positive (HCV) group, and evaluated the clinical course based on duration and severity of hepatic dysfunction. Mean duration of observation was 3.8 years. Results: 1) HBsAg positivity was 11.3% and anti-HCV positivity was 13.3%, respectively. Before transplantation, in HBV group, HBsAg positivity was observed in 83.5% before renal transplantation, and 16.5% patients acquired HBsAg after renal transplantation, In HCV group, anti-HCV positivity was observed 54% before transplantation and 19.6% acquired anti-HCV after renal ransplantation. 2) The prevalence of chronic hpatitis in HBV and HCV grup was not different (25.7% vs. 25.5%). Among those with chronic hepatitis in HBV group, four cases progressed to fulminant hepatic failure, one case progressed end-stage of liver cirrhosis and one case progressed to hepatocelluar carcinoma. However, in HCV group, no case showed progression of chronic hepatitis. 3) Overall mortality of HBV and HCV group 25.3% and 7.8%, respectively (p=0.001): Among twenty fatal cases in HBV group 9 cases were liver disease-related but no liver disease-related death was observed in HCV group. Conclusion: HCV as well as HBV infection is quite prevalent and implortant cause of posttransplant chronic hepatitis, and clinical course of anti-HCV-posi- tive recipients are less aggressive than HBsAg positive recipients.
혈액 투석시 발생하는 저혈압에 대한 Amezinium Methylsulfate(Risumic)의 예방 효과에 대한 다기관 공동연구
김용수(Yong Soo Kim),방병기(Byung Kee Bang),김영옥(Young Ok Kim),송호철(Ho Chul Song),양철우(Chul Woo Yang),박정희(Jung Hee Park),박주현(Joo Hyun Park),김병수(Byung Soo Kim),박철휘(Cheol Whee Park),안석주(Suk Ju Ahn),최의진(Eui Jin C 대한신장학회 2000 Kidney Research and Clinical Practice Vol.19 No.1
N/A Background : Dialysis-induced hypotension is a very common but difficult complication to manage. Amezi-nium methylsulfate is a newly developed sympatho-mimetic agent which has been reported as effective in postural hypotension. We studied the preventive effect of amezinium methylsulfate on dialysis-induced hypo- tension in chronic hemodialysis patients. Methods: Twenty-five hemodialysis(HD) patients who were maintaining on hemodialysis longer than 3 months and had frequent episodes of dialysis hypoten-sion were enrolled in this study. After 4 weeks of observation period, patients received one tablet of ameziniurn 30 minutes prior to every hemodialysis session for 4 weeks. We com mean arterial pressure(MAP), number of hypotensive episodes and number of nursing interventions(defined as position change, bolus injection of saline or 50% dextrose in water, need to decrease transmembrane pressure or discon- tinuation of dialysis) between observation and medi-cation period in each patient. Results: The number of nursing interventions (mean, 2.5±0.9 interventions vs. 1.4±0.9 interventions, p<0.05) and hypotensive episodes(mean, 1.7±0.7 episodes per session vs. 0.9±0.7 episodes per session; p<0.05) decreased significantly in the medication period and the nadir MAP(57±13mmHg vs 70±15mmHg; p<0.05), mid-HD MAP(65±15mmHg vs. 79±15mmHg; p<0.05) and post-HD MAP(66±14mmHg vs 78±16 mmHg ; p<0.05) are higher in the medication period compared with observation period. Conclusion : These results show that amezinium methylsulfate is useful to prevent dialysis-induced hypotension in chronic hemodialysis patients.